Lymphoma & Myeloma Clinical Trials | MD Anderson Cancer Center

Last Updated: 08/21/2024

CAR T/Cellular Therapy

Lymphoma CAR T/Cellular Therapy

Previously Untreated

2020-0872 A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

2022-0463 An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma

Previously Treated

2017-0946 Long-Term Follow-Up Protocol For Subjects Treated With Gene-Modified T Cells

2015-0569 Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy

2023-0079 Allogeneic natural killer T-Cells expressing CD19 specific chimeric antigen receptor and interleukin-15 in relapsed or refractory B-Cell malignancies 2 (ANCHOR2)

2021-0468 Phase I, open label, multicenter, dose escalation study of YTB323 in adult patients with CLL/SLL, DLBCL and ALL

2023-0706 A phase 1b multicenter, open-label, study of JNJ-90009530, an autologous anti-CD20 CAR-T cell therapy in adult participants with relapsed or refractory B-cell Non-Hodgkin lymphoma

2023-0639 Long-term follow-up study for participants previously treated with Ciltacabtagene Autoleucel

2023-0485 An open-label, multicenter phase 2 study Evaluating the Efficacy and Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants with Relapsed/Refractory Large B-Cell Lymphoma after CD19-directed CAR T-cell Therapy

2023-0202 A Phase 1 multicenter study evaluating the safety and efficacy of ACE1831, an Allogeneic CD20-Conjugated Gamma Delta T-Cell therapy, In adult subjects with relapsed/refractory CD20-expressing B-Cell malignancies

2020-0660 Expanded access protocol (eap) for patients receiving lisocabtagene maraleucel that is nonconforming for commercial release

2021-0543 Evaluating the Feasibility Of a Digital Health Coaching for Individuals Following CAR T Therapy

2020-1136 A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363, an Autologous Anti-CD19/CD20 CAR T-cell Therapy, in Subjects With Relapsed and/or Refractory B-cell Lymphoma

2020-1263 Long-term Follow-up Protocol for Subjects Treated with Adicet Bio Allogeneic Gamma Delta T-cell Investigational Products

2020-1137 (CD20): A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (?d) T Cells in Adults with B Cell Malignancies, in Monotherapy and Combination with IL-2

2023-0176 A pilot study for pupillary assessment to predict CAR-T related neurotoxicity

2023-0025 A phase 1 study evaluating SC291, a hypoimmune allogeneic CD19-directed CAR T cell therapy, in relapsed and/or refractory B-cell malignancies (ARDENT)

Myeloma CAR T/Cell Therapy

Previously Treated

2021-0543 Evaluating the Feasibility Of a Digital Health Coaching for Individuals Following CAR T Therapy

2023-0115 A phase 1, multicenter, open-label study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in patients with relapsed/refractory multiple myeloma (CaMMouflage Trial)

Lymphoma Clinical Trials

2021-1003 A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies

Non Hodgkins Lymphoma

Indolent Lymphoma (Follicular, Marginal Zone, Small Lymphocytic Leukemia)

Previously Untreated

2024-0114 A phase 3, multicenter, randomized, open-label trial to evaluate the safety and efficacy of Epcoritamab + Rituximab and Lenalidomide (R^2 ) compared to chemoimmunotherapy in previously untreated follicular lymphoma (EPCORE FL-2).

2023-0063 Phase 2 trial of Obinutuzumab and CC-99282 for patients with previously untreated high tumor burden follicular lymphoma

Previously Treated

2024-0294 A Phase I, open-label, dose escalation study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ONO-7018 in patients with relapsed or refractory Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)

2024-0243 A phase 2 trial of mosunetuzumab and zanubrutinib for patients with relapsed/refractory marginal zone lymphoma

2021-0499 Phase III, Randomized, Open-label, multicenter study evaluating efficacy and safety of mosunetuzumab in combination with lenalidomide in comparison to rituximab in combination with lenalidomide in patients with follicular lymphoma after at least one line

2023-0610 Phase 1, open-label study of Autologous SIRPa-low Macrophages (sirpant-m) administered by intratumoral injection alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory Non-Hodgkin's Lymphoma.

2023-0613 A phase 1/2a, open-label, dose escalation trial of GEN3017 with expansion cohorts in relapsed or refractory CD30+ classical Hodgkin lymphoma and CD30+ non-Hodgkin lymphoma

2021-1214 A Phase 1/2, First in Human, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Triple-specific T-cell Engager 1A46 in Adult Patients with Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies

2022-0394 A Phase lb, Open-Label, Multicenter Study Evaluating the Safety, Pharmacokinetics, And Efficacy of Mosunetuzumab or Glofitamab In Combination With CC-220 And CC-99282 In Patients With B-Cell Non-Hodgkin Lymphoma

2022-0298 A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma

2021-0226 A Phase I/II Open Label, Single Center, Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients with Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

2021-0091 A Multicenter, Phase1, Open-label, Dose-escalation and Expansion Study of TNB-486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-cell Non Hodkins Lymphoma

2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma

2017-0475(UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies

2017-0224 (Ibrutinib): Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

2022-0551 A phase 1/2, open-label study of Valemetostat in combination with Rituximab and Lenalidomide in relapsed or refractory Follicular Lymphoma

2023-0335 A phase 3 randomized, open-label, multicenter study of Zanubrutinib (BGB-3111) plus anti-CD20 antibodies versus Lenalidomide Plus Rituximab in patients with Relapsed/Refractory follicular or marginal zone lymphoma

2022-0459 A phase II trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in patients with relapsed B-cell NHL

2022-0916 A phase 1, first-in-human study of JNJ-80948543, a T-cell redirecting antibody, in participants with NHL and CLL

Aggressive Lymphoma (Large B cell Lymphoma, Diffuse Large B cell Lymphoma, Burkitt's Lymphoma)

Newly diagnosed

2024-1146 Ph3 study GOLSEEK-1 in participants with previously untreated high-risk large B-cell Lymphoma

2021-0369 A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma

2021-0046 Smart Stop: A Phase II trial of Rituximab,Lenalidomide, Acalabrutinib, Tafasitamab prior to and with standard chemotherapy for patients with newly diagnosed DLBCL

2020-0686 A Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-cell Lymphoma

2023-0031 Phase 2 trial of Epcoritamab in combination with Rituximab-mini CVP for older unfit/frail patients or anthracycline-ineligible adult patients with newly diagnosed diffuse large B-cell Lymphoma.

Previously Treated

2024-0431 A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response to first line therapy for large B-cell lymphoma (ALPHA3)

2023-0673 A phase 2 Study of Axicabtagene Ciloleucel and Glofitamab as second-line therapy for relapsed or refractory, or high-risk untreated patients with large B Cell Lymphoma

2023-0610 Phase 1, open-label study of Autologous SIRPa-low Macrophages (sirpant-m) administered by intratumoral injection alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory Non-Hodgkin's Lymphoma.

2023-0485 An open-label, multicenter phase 2 study Evaluating the Efficacy and Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants with Relapsed/Refractory Large B-Cell Lymphoma after CD19-directed CAR T-cell Therapy

2021-1214 A Phase 1/2, First in Human, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Triple-specific T-cell Engager 1A46 in Adult Patients with Advanced CD20 and/or CD19 Positive B-cell Hematologic Malignancies

2021-1169 REAL-MIND: Prospective multicenter observational study of patients with relapsed or refractory diffuse large B-cell lymphoma starting second- or third-line therapy and not receiving autologous stem cell transplant

2022-0147 A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients with Large B-cell Lymphoma who Achieve Partial Remission After CAR T-cell Therapy

PA15-0957 DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

2020-0184 A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

2021-0181 A Multicenter Phase 2 Study of Belantamab mafodotin in Relapsed or Refractory Plasmablastic Lymphoma and ALK+ Large B-cell Lymphoma

2021-0463 An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

2018-1160 (CC-99282): A Phase I, Multi-Center, Open Label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination with Rituximab in Subjects with Relapsed or Refractory Non-Hodgkins Lymphoma

2022-1031 Phase 1/2 multi-center study to evaluate the safety and efficacy of Onct-808 in adult subjects with relapsed or refractory aggressive B-cell malignancies

2023-0079 Allogeneic natural killer T-Cells expressing CD19 specific chimeric antigen receptor and interleukin-15 in relapsed or refractory B-Cell malignancies 2 (ANCHOR2)

Mantle Cell Lymphoma

Previously Untreated

2023-0413 Phase II study of Pirtobrutinib, rituximab (PR) in previously untreated low and intermediate risk MCL (mantle cell lymphoma) patients

2024-0393 A randomized, open-label, phase 3 trial to compare the efficacy and safety of Idecabtagene Vicleucel with Lenalidomide maintenance versus Lenalidomide maintenance therapy alone in adult participants with newly diagnosed multiple myeloma who have suboptimal response after autologous stem cell transplantation (KarMMa-9).

2024-0220 GATE1: A multicenter phase II study of pirtobrutinib, rituximab and venetoclax combination therapy for patients with previously untreated mantle cell lymphoma

2023-0412 A Multicentre, Phase II, Randomized, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment-Naive Mantle Cell Lymphoma (TrAVeRse)

2020-0872 A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

Previously Treated

2023-0502 A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/​or Refractory Multiple Myeloma

2023-0695 Tafasitamab, Lenalidomide and Venetoclax combination therapy for relapsed or refractory Mantle Cell Lymphoma (V-MIND)

2023-0610 Phase 1, open-label study of Autologous SIRPa-low Macrophages (sirpant-m) administered by intratumoral injection alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory Non-Hodgkin's Lymphoma.

2021-1108 Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients

2019-0421 (ACAL): A Phase II Study of Acalabrutinib in Ibrutinib-Intolerant Mantle Cell Lymphoma

2019-1022 (Match): A Pilot Study of Interrogating biological Signaling Pathways Dysregulations and in vitro Screening with Personalized Therapies in resistant Mantle Cell Lymphoma (MCL) - the MCL Match Trial

2017-0475 (UC-961): A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies

2022-0722 A single-Arm, open-label, multicenter phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of Bcl-2 inhibitor BGB-11417 in patients with relapsed or refractory Mantle Cell Lymphoma

Hodgkin Lymphoma

Newly Diagnosed

2022-1065 NCI10590: NORM: nodular lymphocyte-predominant Hodgkin lymphoma patients treated in a randomized phase 2 trial with either Rituximab or Mosunetuzumab

Previously Treated

2024-0430 A phase 1 first in human study of ARV-393 in adult participants with advanced Non-Hodgkin's Lymphoma

2022-1065 NCI10590: NORM: nodular lymphocyte-predominant Hodgkin lymphoma patients treated in a randomized phase 2 trial with either Rituximab or Mosunetuzumab

2022-1065 NCI10590: NORM: nodular lymphocyte-predominant Hodgkin lymphoma patients treated in a randomized phase 2 trial with either Rituximab or Mosunetuzumab

2023-0613 A phase 1/2a, open-label, dose escalation trial of GEN3017 with expansion cohorts in relapsed or refractory CD30+ classical Hodgkin lymphoma and CD30+ non-Hodgkin lymphoma

2021-1033 An open-label, multi-center, non-randomized phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell Lymphoma

T-Cell Lymphoma

Newly Diagnosed

2024-0115 A phase 3, randomized, open-label study comparing the efficacy and safety of the combination of Beleodaq-CHOP or Folotyn-COP to the CHOP regimen alone in newly diagnosed patients with peripheral T cell lymphoma.

Previously Treated

2024-1024 SPIND: Use of Linperlisib in a patient with R/R peripheral T/NK cell or cutaneous T cell lymphoma

2023-0962 A phase 3 study of ITK inhibitor Soquelitinib vs physician s choice SOC treatment in R/R Lymphoma

2017-0927 A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphomas

2018-1064 (TTI-622): A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advance Relapsed or Refractory Lymphoma or Myeloma

2021-1033 An open-label, multi-center, non-randomized phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell Lymphoma

Multiple Myeloma Clinical Trials

Newly Diagnosed

2023-0617 SWOG S2209: A phase III randomized trial for newly diagnosed Multiple Myeloma (NDMM) patients considered frail or in a subset of "intermediate fit" comparing upfront three-drug induction regimens followed by double- or single-agent maintenance.

2022-0417 SMOLDERING MYELOMA REGISTRATION TRIAL (SMRT STUDY)

2021-0442 Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)

2021-0191 (DETER-SMM) EAA173: Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

2020-0431 A Phase 1 with Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

2023-0363 Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in previously untreated patients with symptomatic multiple Myeloma (Linker-MM4 Study)

Previously Treated

2024-1162 A Ph 1b/2 study of GC012F in subjects with relapsed/refractory multiple myeloma

2024-0271 Ph I/II study to evaluate anti-GPRC5D CAR-T cell product in R/R multiple myeloma.

2021-0309 Clinical and Patient Reported Outcomes for Individuals with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab: Real-World Insights from Patient Reported, Wearable, and Qualitative Data in the Context of a Digital Health Coaching Program

2023-0502 A phase 1, multicenter, open-label study to evaluate the safety and preliminary efficacy of BMS-986393 in novel combinations in participants with relapsed and/or refractory multiple myeloma and determine the recommended dose for each add-on investigational component

NCI10076: A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma

2023-0719 A phase 3, two-stage, randomized, multicenter, open-label study comparing Mezigdomide(CC-92480), Bortezomib and Dexamethasone (MeziVd)versus Pomalidomide,Bortezomib and Dexamethasone (PVD) in subjects with Relapsed or Refractory Multiple myeloma (RRMM): successor-1

2023-0687 An open-label, randomized, phase 3 study of Linvoseltamab (REGN5458; anti-BCMA x anti-CD3 Bispecific Antibody) versus the combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in patients with relapsed/refractory multiple myeloma (LINKER-MM3)

2023-0199 SPIND: Compassionate use of Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma

2023-0527 Phase I/II open label study of Belumosudil Mesylate alone, and in combination with Dexamethasone, in patients with relapsed/refractory multiple myeloma

2023-0453 A phase 1b/2 dose escalation and expansion study of the combination of the bispecific T cell redirection antibodies Talquetamab and Teclistamab in participants with relapsed or refractory multiple myeloma

NCI10076 A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination with Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma

2020-1229 A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma

2020-0973 Expanded Access Protocol (EAP) for Subjects receiving Idecabtagene Vicleucel that is Nonconforming for Commercial release

2016-0172 Quality of Life in Patients with Asymptomatic Monoclonal Gammopathies

2019-0499 (CT053): Open label, multi-center, phase 1b clinical trial to evaluate the safety and efficacy of autologous CAR-BCMA T cells (CT053) in patients with relapsed and/or refractory multiple myeloma

2018-0192 (XmAb13676): A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 in Patients with CD20-Expressing Hematologic Malignancies

2022-0598 A phase II study of CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma.

2022-0993 International Myeloma foundation study of the outcomes of patients with relapsed or high-risk Myeloma receiving Novel Immunotherapies

2023-0115 A phase 1, multicenter, open-label study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in patients with relapsed/refractory multiple Myeloma (CaMMouflage Trial)

2023-0195, 2023-0197, 2023-0199 SPIND: Compassionate use of Belantamab Mafodotin for relapsed and refractory multiple myeloma

2023-0252 A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (TalD) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

Other Clinical Trials

2024-1019 SWOG: Study S2213 a phase III, randomized study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DaraVCD) Induction followed by Autologous Stem Cell Transplant or Dara-VCD consolidation and Daratumumab maintenance in patients with newly diagnosed AL Amyloidosis

2024-0391 Project DANCES (diversity in Aya caNCEr survivors)

2024-0453 An open-label, dose escalation and dose expansion trial evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered CA-4948 in patients with relapsed or refractory primary central nervous system lymphoma

2024-0408 An analysis of manufacturing outcomes with patient factors from multiple myeloma patients prescribed ciltacabtagene autoleucel

2024-0160 A phase 1/2 study of linvoseltamab in patients with relapsed or refractory systemic light chain amyloidosis 2024-0198 A phase 1/2 dose evaluation and cohort expansion study of the safety and efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX131) in adult subjects with relapsed/refractory hematologic malignancies.

2023-0942 Study of AZD3470 in participants with relapsed/refractory Hematologic Malignancies.

2023-0864 A pilot study of Emapalumab for the treatment of CAR T-Cell therapy-associated prolonged cytopenia

2023-0738 An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

2023-0581 A randomized trial of fecal microbiota transplantation for remedying antibiotics-induced microbiota dysbiosis in lymphoma patients receiving Axicabtagene Ciloleucel therapy

2022-0224 The impact of molecular heterogeneity on response to targeted and cellular therapies in T and NK cell lymphoma

2022-0358 Real-World Outcomes in Patients with Relapsed or Refractory (R/R) Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)

2021-0393 Analysis of apheresis and infusion product retains from lymphoma patients treated with standard of care axicabtagene ciloleucel

2005-0656 A Collection of Blood and Tissue Samples from Patients with Lymphoma and/or Myeloma and Normal Donors

2022-0784 Myeloma Genetics and Epidemiology - Genetica y Epidemiologia de Mieloma (GEM Study)

2022-0533 Disparities among Childhood and Adolescent/Young Adult (AYA) Cancer Populations

PA15-0575 Observational prospective research study in monoclonal Gammopathies leadINg to myeloma (ORIGIN study)

2021-1088 A Multicenter, Open-label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma with or without HIV

2021-0758 Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

2022-0396 Feasibility of Combined Genomics/Transcriptomics for Patients with Lymphoma

2020-0238 A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects With R/R T or B Cell Malignancies

2021-0392 Collection of blood samples from normal donors 2021-0440 A Collection of Blood and Tissue Samples from Patients with Amyloidosis and/or Monoclonal Gammopathies (including Lymphoplasmacytic Lymphoma) and Normal Donors 2021-0816 A Study to Evaluate Long-Term Safety of CAR-T Cell Therapy in Patients with Hematologic Malignancies 2022-0052 A Prospective Study Of Conventional Bone Marrow Biopsies And Bone Marrow Biopsies Performed Through An Indwelling Bone Marrow Port, Using A Modified PROMIS Pain Intensity Scale For Pain Assessment 2022-0167 Precision Approaches to Treat Mantle Cell Lymphoma: Integrating Multi-omics Based Models 2022-0193 Outcomes of Cutaneous T-Cell Lymphoma Patients on Mogamulizumab PA14-0094 The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Protocol

2021-0049 HSP70 as a target for New drugs in Multiple Myeloma and Lymphoma

2023-0218 Pilot study to assess the feasibility, cost-effectiveness, and patient-reported outcomes of outpatient CAR T-cell administration for patients with Multiple Myeloma

2023-0253 Intermediate-size population expanded access program (EAP) for ciltacabtagene autoleucel (cilta-cel) out-of-specification (OOS) in patients with multiple myeloma

2022-0492 PET adapted Brentuximab Vedotin and Pembrolizumab in combination with Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

2022-0603 Feasibility and clinical utility of cell-free DNA (cfDNA) in identifying actionable alterations and minimal residual disease for lymphoma patients across community centers in Texas.

2023-0329 An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)

2022-0918 Expanded access study for the treatment of patients with commercially out-of-specification Axicabtagene Ciloleucel

2023-0420 Phase 1/2 study of IDP 023 as a single agent and in combination with antibody therapies in patients with advanced Hematologic cancers.

2020-0797 Mechanisms of Late-effects in Childhood and AYA Cancer Survivors